Invivyd Inc
NASDAQ:IVVD
Invivyd Inc
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in Waltham, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2021-08-06. The firm is engaged in developing antibodies to transcend the limits of naturally occurring immunity and provide protection from viral diseases, beginning with COVID-19. Its technology works at the intersection of virology, predictive modeling, and antibody engineering. Its platform approach yields a pipeline of engineered antibodies designed to provide neutralization across past and current SARS-CoV-2 variants of concern, including wildtype, Beta, Delta, and Omicron BA.1, BA.2, BA.5, and BA.2.75. The firm generates a pipeline of products for use in both the prevention and treatment of disease. Its advanced pipeline candidate includes adintrevimab, an investigational monoclonal antibody that is used against multiple variants of concern for the prevention and treatment of COVID-19. The firm also has multiple discovery stage candidates for the prevention of seasonal influenza.
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in Waltham, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2021-08-06. The firm is engaged in developing antibodies to transcend the limits of naturally occurring immunity and provide protection from viral diseases, beginning with COVID-19. Its technology works at the intersection of virology, predictive modeling, and antibody engineering. Its platform approach yields a pipeline of engineered antibodies designed to provide neutralization across past and current SARS-CoV-2 variants of concern, including wildtype, Beta, Delta, and Omicron BA.1, BA.2, BA.5, and BA.2.75. The firm generates a pipeline of products for use in both the prevention and treatment of disease. Its advanced pipeline candidate includes adintrevimab, an investigational monoclonal antibody that is used against multiple variants of concern for the prevention and treatment of COVID-19. The firm also has multiple discovery stage candidates for the prevention of seasonal influenza.
Revenue Growth: Revenue increased 11% quarter-on-quarter and 41% year-over-year, reflecting stronger market awareness.
Strong Capital Position: Invivyd raised approximately $87 million, leaving the company well-funded to execute pivotal studies and expand commercialization ahead of the VYD2311 launch.
Pipeline Progress: The pivotal program for VYD2311 is on track to start by year-end, with top-line data expected in mid-2026.
Commercial Expansion: Over 15,000 GPO sites are now contracted, and 1,200+ sites are offering PEMGARDA infusions; 76% of accounts are reordering.
No Plans to Sunset PEMGARDA: Management does not expect to discontinue PEMGARDA, even after VYD2311's anticipated approval.
